SLC5A2 and type 2 diabetes mellitus: Given the limited therapeutic options currently available for MASLD and the favorable safety profile of SGLT2 inhibitors, these agents warrant consideration in the management of MASLD patients, especially those with T2DM or high cardiovascular risk.